|
Current and emerging strategies for management of myelodysplastic syndromes
|
Dec 2020
|
Blood reviews
|
myelodysplastic syndromes (MDS)
|
|
Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium
|
Dec 2020
|
Cancer Medicine
|
myelodysplastic syndromes (MDS)
|
|
Paroxysmal nocturnal hemoglobinuria: current treatments and unmet needs
|
Dec 2020
|
Journal of Managed care and specialty pharmacy
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Paroxysmal nocturnal hemoglobinuria: patient journey and burden of disease
|
Dec 2020
|
Journal of Managed care and specialty pharmacy
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Paroxysmal nocturnal hemoglobinuria: role of the complement system, pathogenesis, and pathophysiology
|
Dec 2020
|
Journal of Managed care and specialty pharmacy
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab
|
Dec 2020
|
European Journal of Haematology
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Frequency and perturbations of various peripheral blood cell populations before and after eculizumab treatment in paroxysmal nocturnal hemoglobinuria
|
Dec 2020
|
Blood, cells, molecules & diseases
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Survival following relapse after allogeneic hematopoietic cell transplantation for acute leukemia and myelodysplastic syndromes
|
Dec 2020
|
Hematology/oncology and stem cell therapy
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|
|
Existing agents, novel agents, or transplantation for high-risk MDS
|
Dec 2020
|
Hematology. American Society of Hematology. Education Program
|
myelodysplastic syndromes (MDS)
|
|
Therapy for lower-risk MDS
|
Dec 2020
|
Hematology. American Society of Hematology. Education Program
|
myelodysplastic syndromes (MDS)
|
